Medivir is developing alovudine, an anti-HIV compound for the potential treatment of drug-resistant HIV infection. A phase IIa trial involving patients with multiresistant HIV was initiated in October 2001 and by July 2002, the trial had been completed.

Alovudine Medivir / S. Rusconi. - In: CURRENT OPINION IN INVESTIGATIONAL DRUGS. - ISSN 1472-4472. - 4:2(2003 Feb), pp. 219-23-223.

Alovudine Medivir

S. Rusconi
Primo
2003-02

Abstract

Medivir is developing alovudine, an anti-HIV compound for the potential treatment of drug-resistant HIV infection. A phase IIa trial involving patients with multiresistant HIV was initiated in October 2001 and by July 2002, the trial had been completed.
Clinical Trials, Phase II as Topic; HIV Infections; Humans; Clinical Trials, Phase I as Topic; HIV Reverse Transcriptase; Dideoxynucleosides; HIV-1; Structure-Activity Relationship; Reverse Transcriptase Inhibitors
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/188798
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 6
  • ???jsp.display-item.citation.isi??? ND
social impact